TickerFacts.

Nexentis Technologies Inc. (NXTS): Operating Income

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2024-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$4.23M
Year ended 2025-12-31
2018-12-31: -$518.7K2019-12-31: -$1.93M2020-12-31: -$1.35M2021-12-31: -$4.70M2022-12-31: -$5.82M2023-12-31: -$7.58M2024-12-31: -$3.28M2025-12-31: -$4.23M-$4.23M
2018-12-31 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$4.23Mn/m2026-03-31, From 2025-01-01
2024-12-31-$3.28Mn/c2026-03-31, From 2024-01-01
2023-12-31-$7.58Mn/m2025-03-31, From 2023-01-01
2022-12-31-$5.82Mn/m2024-04-01, From 2022-01-01
2021-12-31-$4.70Mn/m2023-03-27, From 2021-01-01
2020-12-31-$1.35Mn/m2022-03-31, From 2020-01-01
2019-12-31-$1.93Mn/m2021-03-29, From 2019-01-01
2018-12-31-$518.7Kn/a2020-03-30, From 2018-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Nexentis Technologies Inc. (NXTS)2025-12-31-$4.23Mn/m
Evofem Biosciences, Inc. (EVFM)2025-12-31$3.37Mn/m
Jyong Biotech Ltd. (MENS)2025-12-31-$2.61Mn/m
Abvc Biopharma, Inc. (ABVC)2025-12-31-$7.15Mn/m
Annovis Bio, Inc. (ANVS)2025-12-31-$29.70Mn/m
Galectin Therapeutics Inc (GALT)2025-12-31-$20.09Mn/m
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$231.0Kn/m
Phio Pharmaceuticals Corp. (PHIO)2025-12-31-$9.22Mn/m
Lftd Partners Inc. (LIFD)2025-12-31$913.2Kn/m

Compare NXTS, EVFM, MENS, ABVC side by side · Screen every company in Pharmaceutical Preparations ↗